The total return over the past 12 months is -41.77% vs. +16.94% for the S&P 500. So far it's up +25.47% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (41.77%) | (53.87%) | (71.98%) | (52.81%) | N/A | N/A |
| Total Return CAGR | (41.77%) | (53.87%) | (71.98%) | (52.81%) | N/A | N/A |
| Revenue CAGR | N/A | +635.31% | N/A | N/A | +106.09% | +40.04% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
InMed Pharmaceuticals Inc. (INM)
| Year | Start price | End price | INM Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.06 | $1.33 | +25.47% | +14.51% | +10.96% |
| 2025 | $4.74 | $1.06 | (77.64%) | +17.72% | (95.36%) |
| 2024 | $8.32 | $4.74 | (43.03%) | +24.89% | (67.92%) |
| 2023 | $40.40 | $8.32 | (79.41%) | +26.19% | (105.60%) |
| 2022 | $655.00 | $40.40 | (93.83%) | (18.17%) | (75.66%) |
| 2021 | $1,645.00 | $655.00 | (60.18%) | +28.74% | (88.92%) |
| 2020 | $2,970.00 | $1,645.00 | (44.61%) | +18.37% | (62.98%) |
| 2019 | $4,207.60 | $2,970.00 | (29.41%) | +31.22% | (60.63%) |
| 2018 | $17,572.60 | $4,207.60 | (76.06%) | (4.56%) | (71.50%) |
| 2017 | $2,805.00 | $17,572.60 | +526.47% | +21.70% | +504.77% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
